We're crowdfunding! Own a part of our business. Capital at Risk.
View our pitch

Stablepharma actively partners with global vaccine manufacturers, world-class academic institutions, leading Contract Manufacturing Organisations (CMOs) as well as NGOs and Government Organisations to advance its development programmes 

Stablepharma, with its commercial and academic partners, has generated strong in-vitro and in-vivo data for its vaccine programmes including Tetadif (Td) and COVID mRNA. Studies have shown repeatedly that StablevaX™ elicits a strong immune response in animals even after being exposed to high temperatures for long periods of time.

Stablepharma has a strategic R&D and commercialisation partnership agreement in place with the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio) with the aim to produce the world’s first ‘fridge free’ Td-StablevaX™ vaccine.

We have established partnerships with two leading UK Universities: University of Southampton to conduct our First in Human Clinical Trials for the Td vaccine; and the University of Strathclyde to progress our mRNA stabilisation project for Covid-19 vaccines.

Stablepharma has worked with the UK’s The National Institute for Biological Standards and Control (NIBSC) to conduct animal trials, in order to confirm that the StablevaX™ tetanus vaccine induces the same level of antibody response as the positive control vaccine.

Innovate UK has provided grant funding to Stablepharma to progress the R&D and product development work for the StablevaX™ Td vaccine.

Our white paper

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose

A world changing invention for the stabilisation of vaccines.

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose

Get in touch to receive further information on Stablepharma